EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors

Michael B Mumphrey, Noshad Hosseini, Abhijit Parolia, Jie Geng, Weiping Zou, Malini Raghavan, Arul Chinnaiyan, Marcin Cieslik

Cell Reports · 2023

DOI: 10.1016/j.celrep.2023.112965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023. Verfasst von Michael B Mumphrey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class I, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disruption of antigen presentation via loss of major histocompatibility complex (MHC) expression is a strategy whereby cancer cells escape immune surveillance and develop resistance to immunotherapy. Here, we develop the personalized genomics algorithm Hapster and accurately call somatic mutations within the MHC genes of 10,001 primary and 2,199 metastatic tumors, creating a catalog of 1,663 non-synonymous mutations that provide key insights into MHC mutagenesis. We find that MHC class I genes are among the most frequently mutated genes in both primary and metastatic tumors, while MHC class II mutations are more restricted. Recurrent deleterious mutations are found within haplotype- and cancer-type-specific hotspots associated with distinct mutational processes. Functional classification of MHC residues reveals significant positive selection for mutations disruptive to the B2M, peptide, and T cell binding interfaces, as well as to MHC chaperones.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histocompatibility Antigens Class INeoplasmsHumansHLA AntigensT-LymphocytesHistocompatibility Antigens Class IIMutation

Stichwörter der Autor:innen

CP: CancerCP: ImmunologyHLAMHCcancerevolutiongenomicsimmunogeneticsselectionsomatic mutations

Substanzen

Histocompatibility Antigens Class IHLA AntigensHistocompatibility Antigens Class II

Autor:innen und Institutionen

  • Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Microbiology & Immunology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Microbiology & Immunology, University of Michigan, Ann Arbor, MI 48109, USA; Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan, Ann Arbor, MI 48109, USA; University of Mi…
  • Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA; Michigan Center for Translational Patho…

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • Howard Hughes Medical Institute

Zitieren

APA

Mumphrey, M. B., Hosseini, N., Parolia, A., Geng, J., Zou, W., Raghavan, M., Chinnaiyan, A., & Cieslik, M. (2023). Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors. Cell Reports. https://doi.org/10.1016/j.celrep.2023.112965

Vancouver

Mumphrey MB, Hosseini N, Parolia A, Geng J, Zou W, Raghavan M, et al. Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors. Cell Reports. 2023. doi:10.1016/j.celrep.2023.112965

BibTeX
@article{Mumphrey2023,
  author = {Mumphrey, Michael B and Hosseini, Noshad and Parolia, Abhijit and Geng, Jie and Zou, Weiping and Raghavan, Malini and Chinnaiyan, Arul and Cieslik, Marcin},
  title = {Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors},
  journal = {Cell Reports},
  year = {2023},
  doi = {10.1016/j.celrep.2023.112965}
}
Kostenlos starten →